Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

First Posted Date
2013-01-17
Last Posted Date
2015-05-07
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT01769911
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2013-01-01
Last Posted Date
2024-01-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
29
Registration Number
NCT01758328
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

First Posted Date
2012-12-10
Last Posted Date
2018-07-11
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
2
Registration Number
NCT01745913
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

First Posted Date
2012-12-10
Last Posted Date
2023-01-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
5
Registration Number
NCT01746173
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

First Posted Date
2012-11-22
Last Posted Date
2020-02-05
Lead Sponsor
Columbia University
Target Recruit Count
60
Registration Number
NCT01731886
Locations
🇺🇸

Columbia University, New York, New York, United States

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

First Posted Date
2012-11-20
Last Posted Date
2024-06-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT01729091
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

First Posted Date
2012-11-16
Last Posted Date
2013-10-23
Lead Sponsor
Delcath Systems Inc.
Registration Number
NCT01728051
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States

🇺🇸

Sky Ridge Medical Center, Englewood, Colorado, United States

🇺🇸

University of Pittsburg Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 3 locations

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

First Posted Date
2012-10-11
Last Posted Date
2020-10-23
Lead Sponsor
St. Anna Kinderkrebsforschung
Target Recruit Count
3300
Registration Number
NCT01704716
Locations
🇵🇱

Medical University in Gdansk, Gdansk, Poland

🇵🇱

Children's University Hospital in Lublin, Lublin, Poland

🇵🇱

University of Medical Sciences Poznan, Poznan, Poland

and more 122 locations

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

First Posted Date
2012-10-10
Last Posted Date
2018-12-19
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
75
Registration Number
NCT01702961
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

First Posted Date
2012-10-08
Last Posted Date
2022-09-21
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
78
Registration Number
NCT01702831
Locations
🇨🇦

Saint John Regional Hospital, 5DN Research Department, 400 University Ave, Saint John, New Brunswick, Canada

🇨🇦

Cross Cancer Institute 11560 University Ave, Edmonton, Alberta, Canada

🇨🇦

Queen Elizabeth II Health Sciences Centre., Halifax, Nova Scotia, Canada

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy